Heat Biologics EBIT

Heat Biologics (HTBX) currently reports a EBIT of $-43T as of September 2025. That compares with $-35M in the prior-year period — down 122015520.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Heat Biologics's EBIT history and peer comparisons.

Heat Biologics's EBIT decreased from $-35M to $-43T — a 122015520.4% year-over-year decrease (period ending September 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Heat Biologics's EBIT of $-43T is lower than the Healthcare sector average of $22B. That is roughly 193246.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Heat Biologics reported $-43T in EBIT as of September 2025. That compares with $-35M in the prior-year period — down 122015520.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-43T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Heat Biologics, and consider following HTBX for alerts when major investors trade the stock.